Zevra Reports Positive Phase 2 Results for Idiopathic Hypersomnia Drug Candidate
The positive top-line results of the phase 2 trial support the safety and tolerability of KP1077.
The positive top-line results of the phase 2 trial support the safety and tolerability of KP1077.
Quality sleep can be hard to come by during a heat wave, especially for those who don’t have air conditioning.
Axsome Therapeutics' CRESCENDO survey finds 77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated.
Many sleep clinicians and researchers are on the market for new actigraphy devices after the discontinuation of Actiwatch support last December.
The company, known for research-based, FDA-listed sleep products for babies, children, and adults, is rebranding under a collective new brand identity.